Daniel E. Salazar

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

John T. Brandt, Sandra Close, Stephen J. Iturria et al. · Journal of Thrombosis and Haemostasis · 2007 · 730 citations

Medicine, Pharmacokinetics, Pharmacology +14

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

Stuart J. Connolly, Indravadan Patel, Daniel E. Salazar et al. · Thrombosis and Haemostasis · 2010 · 343 citations

Medicine, Pharmacology, Pharmacotherapy +12

Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

Nazar Farid, Christopher D. Payne, D. S. Small et al. · Clinical Pharmacology & Therapeutics · 2007 · 322 citations

Medicine, Pharmacokinetics, Pharmacology +17

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

David S. Small, Nagy A. Farid, Christopher D. Payne et al. · The Journal of Clinical Pharmacology · 2008 · 316 citations

Medicine, Pharmacokinetics, Pharmacology +10

Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass

Daniel E. Salazar, George B. Corcoran · The American Journal of Medicine · 1988 · 250 citations

Pharmacy, Pharmacokinetics, Pharmacology +17